^
    Back
    Association details:
    Biomarker:NOTCH3 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Tevimbra (tislelizumab-jsgr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Thorac Oncol
    Title:

    Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial

    Published date:
    09/28/2022
    Excerpt:
    The phase 3 RATIONALE-303 trial (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced non-small cell lung cancer (NSCLC)....Exploratory biomarker analyses showed the potential association of NOTCH1–4 mutations with improved tislelizumab efficacy for both OS and PFS...
    DOI:
    https://doi.org/10.1016/j.jtho.2022.09.217
    Trial ID:
    RATIONALE-303